Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes

• US 5,503,827 A
• Filed: 02/15/1994
• Issued: 04/02/1996
• Est. Priority Date: 08/15/1991
• Status: Expired due to Term

• Current Assignee: Boehringer Mannheim GmbH (Roche Holding AG)
• Original Assignee: Boehringer Mannheim GmbH (Roche Holding AG)
• Inventors: Winter, Gerhard, Gruber, Werner, Woog, Heinrich, Demmer, Fritz, Markl, Hans-Jorg
• Primary Examiner(s): Chan, Christina Y.
• Assistant Examiner(s): LEITH, NANCY J
• Application Number:
  US08/193,002
• Time in Patent Office: 777 Days
• Field of Search: 514/12, 514/21, 514/8, 424/85.1, 530/351, 530/350, 530/380, 530/395, 530/397, 530/399, 530/829
• US Class Current: 424/85.1
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/186 Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: Y10S 530/829 Blood

Abstract

The present invention concerns a process for the production of well-tolerated, preserved injection or infusion solutions containing human protein.

Claims

1. A process for the production of preserved isolated or recombinantly produced human protein-containing pharmaceutical preparations suitable for use as injection or infusion solutions in the form of multi-dose preparations, comprising forming a solution of the isolated or recombinantly produced human protein and at least one preservative selected from the group consisting of chlorobutanol, benzyl alcohol, benzalkonium chloride and mixtures thereof, in the absence of a mineral suspension, wherein the concentration of the preservative in the multi-dose preparation is 0.001 to 2 w/v %.

2. Process of claim 1, wherein the solution is an aqueous solution.

3. Process of claim 2, wherein the preservative is added to an aqueous solution of the human protein.

4. Process of claim 3, wherein the concentration is 0.01 to 1 w/v %.

5. Process of claim 3, wherein the preservative is a mixture.

6. Process of claim 2, wherein the preservative is chlorobutanol (1,1,1-trichloro-2-methyl-2-propanol) which is present in the solution in a concentration of about 2-5 mg/ml.

7. Process of claim 2, wherein the preservative is benzyl alcohol which is present in the solution in a concentration of about 1-5 mg/ml.

8. Process of claim 2, wherein benzalkonium chloride is present in the solution in a concentration of about 0.01-0.05 mg/ml.

9. Process of claim 2, wherein the human protein is selected from the group consisting of EPO, G-CSF and proteins with plasminogen activator-like activity.

10. Process of claim 2, wherein the buffer capacity of the preparation is adjusted to a value of up to 10 mVa/l.

11. Process of claim 10, wherein the buffer capacity of the preparation is adjusted by the addition to the solution of a well tolerated buffer substance selected from the group consisting of glycol, sodium citrate, alkali phosphates, alkali carbonates, amino acid salts, malic acid salts, maleic acid, fumaric acid, tartaric acid, aspartic acid and mixtures thereof.

12. Process of claim 2, wherein the titration acidity of the preparation is adjusted to a value of up to 15 mVal/l before administration to a patient.

13. Process of claim 12, wherein the titration acidity of the preparation is adjusted by the addition to the solution of a well tolerated buffer substance selected from the group consisting of glycol, sodium citrate, alkali phosphates, alkali carbonates, amino acid salts, malic acid salts, maleic acid, fumaric acid, tartaric acid, aspartic acid and mixtures thereof.

14. Process of claim 2, wherein said preservative is a mixture of benzyl alcohol and benzalkonium chloride present in concentrations of up to 10 mg/ml and up to 0.1 mg/ml, respectively.

15. Process of claim 2, wherein the preservative is a mixture of benzyl alcohol and chlorobutanol present in concentrations of up to 10 mg/ml each.

16. Process of claim 2, wherein the preservative is a mixture of chlorobutanol, benzyl alcohol and benzalkonium chloride present in concentrations of up to 10 mg/ml, up to 10 ml/mg and up to 0.1 mg/ml, respectively.

17. Process of claim 2, wherein the preservative is a mixture of benzyl alcohol present in a concentration of 3 to 6 mg/ml and benzalkonium chloride present in a concentration of 0.1 to 0.025 mg/ml.

18. A pharmaceutical preparation in the form of a multidose-formulation comprising an aqueous solution containing an isolated or recombinantly produced human protein and 0.001 to 2 w/v % of at least one preservative selected from the group consisting of chlorobutanol (1,1,1-trichloro-2-methyl-2-propanol), benzyl alcohol, benzalkonium chloride and mixtures thereof in the absence of a mineral suspension.

19. Preparation of claim 18, wherein the concentration of the preservative in the solution is about 0.1 to about 2.0 w/v %.

20. Preparation of claim 19, wherein the concentration is about 0.01 to about 0.3 w/v %.

21. Preparation of claim 18 wherein the preservative is a mixture.

22. Preparation of claim 18 wherein the preservative is chlorobutanol (1,1,1-trichloro-2-methyl-2-propanol) which is present in the solution in a concentration of about 2-5 mg/ml.

23. Preparation of claim 18, wherein the preservative is benzyl alcohol which is present in the solution in a concentration of about 1-5 mg/ml.

24. Preparation of claim 18, wherein the preservative is benzalkonium chloride which is present in the solution in a concentration of about 0.01-0.05 mg/ml.

25. Preparation of claim 18, wherein the human protein is selected from the group consisting of EPO, G-CSF and proteins with plasminogen activator-like activity.

26. Preparation of claim 18, wherein the buffer capacity of the preparation is adjusted to a value of up to 10 mVa/l.

27. Preparation of claim 26, wherein the buffer capacity of the preparation is adjusted by the addition to the solution of a well tolerated buffer substance selected from the group consisting of glycol, sodium citrate, alkali phosphates, alkali carbonates, amino acid salts, malic acid salts, maleic acid, fumaric acid, tartaric acid, aspartic acid and mixtures thereof.

28. Preparation of claim 18, wherein the titration acidity of the preparation is adjusted to a value of up to 15 mVal/l before administration to a patient.

29. Preparation of claim 28, wherein the titration acidity of the preparation is adjusted by the addition to the solution of a well tolerated buffer substance selected from the group consisting of glycol, sodium citrate, alkali phosphates, alkali carbonates, amino acid salts, malic acid salts, maleic acid, fumaric acid, tartaric acid, aspartic acid and mixtures thereof.

30. Preparation of claim 18, wherein the preservative is a mixture of benzyl alcohol and benzalkonium chloride present in concentrations of up to 10 mg/ml and up to 0/1 mg/ml, respectively.

31. Preparation of claim 18, wherein the preservative is a mixture of benzyl alcohol and chlorobutanol present in concentrations of up to 10 mg/ml each.

32. Preparation of claim 18, wherein the preservative is a mixture of chlorobutanol, benzyl alcohol and benzalkonium chloride present in concentrations of up to 10 mg/ml, up to 10 mg/ml and up to 0.1 mg/ml, respectively.

33. Preparation of claim 18, wherein the preservative is a mixture of benzyl alcohol present in a concentration of 3 to 6 mg/ml and benzalkonium chloride present in a concentration of 0.1 to 0.025 mg/ml.

34. A kit for the preparation of a human protein-containing pharmaceutical injection or infusion solution, comprising a packaged lyophilized human protein and a separately packaged aqueous reconstitution solvent containing a preservative selected from the group consisting of chlorobutanol, benzyl alcohol, benzalkonium chloride and mixtures thereof in an amount to provide a concentration of the preservative in the injection or infusion solution of 0.001 to 2 w/v %, wherein said kit does not contain a mineral suspension.

35. A process for the production of preserved human protein-containing pharmaceutical preparations suitable for use as injection or infusion solutions in the form of multi-dose preparations, comprising forming an aqueous solution of the human protein and a mixture of at least two preservatives selected from the group consisting of chlorobutanol, benzyl alcohol and benzalkonium chloride in the absence of a mineral suspension, wherein the concentration of the preservatives in the multi-dose preparation is 0.001 to 2 w/v %.

36. Process of claim 35, wherein the preservative is added to an aqueous solution of the human protein.

37. Process of claim 36, wherein the concentration is 0.01 to 1 W/V %.

38. Process of claim 35, wherein one preservative is chlorobutanol (1,1,1-trichloro-2-methyl-2-propanol) which is present in the solution in a concentration of about 2-5 mg/ml.

39. Process of claim 35, wherein one preservative is benzyl alcohol which is present in the solution in a concentration of about 1-5 mg/ml.

40. Process of claim 35, wherein benzalkonium chloride is present in the solution in a concentration of about 0.01-0.05 mg/ml.

41. Process of claim 35, wherein the human protein is selected from the group consisting of EPO, G-CSF and proteins with plasminogen activator-like activity.

42. Process of claim 35, wherein the buffer capacity of the preparation is adjusted to a value of up to 10 mVa/l.

43. Process of claim 42 wherein the buffer capacity of the preparation is adjusted by the addition to the solution of a well tolerated buffer substance selected from the group consisting of glycol, sodium citrate, alkali phosphates, alkali carbonates, amino acid salts, malic acid salts, maleic acid, fumaric acid, tartaric acid, aspartic acid and mixtures thereof.

44. Process of claim 35, wherein the titration acidity of the preparation is adjusted to a value of up to 15 mVal/l before administration to a patient.

45. Process of claim 44, wherein the titration acidity of the preparation is adjusted by the addition to the solution of a well tolerated buffer substance selected from the group consisting of glycol, sodium citrate, alkali phosphates, alkali carbonates, amino acid salts, malic acid salts, maleic acid, fumaric acid, tartaric acid, aspartic acid and mixtures thereof.

46. Process of claim 35, wherein the preservatives are a mixture of benzyl alcohol and benzalkonium chloride present in concentrations of up to 10 mg/ml and up to 0.1 mg/ml, respectively.

47. Process of claim 35, wherein the preservatives are a mixture of benzyl alcohol and chlorobutanol present in concentrations of up to 10 mg/ml each.

48. Process of claim 35, wherein the preservatives are a mixture of chlorobutanol, benzyl alcohol and benzalkonium chloride present in concentrations of up to 10 mg/ml, up to 10 mg/ml and up to 0.1 mg/ml, respectively.

49. The process according to claim 35, further comprising

removing the preservative from said aqueous solution,

lyophilizing said aqueous solution to produce a lyophilisate, and

then reconstituting said lyophilisate with a reconstitution solution containing preservative to produce said multi-dose preparation.

50. Process of claim 35, wherein the preservatives are a mixture of benzyl alcohol present in a concentration of 3 to 6 mg/ml and benzalkonium chloride present in a concentration of 0.1 to 0.025 mg/ml.

51. A pharmaceutical preparation comprising an aqueous solution containing a human protein and 0.001 to 2 w/v % of a mixture of at least two preservatives selected from the group consisting of chlorobutanol(1,1,1-trichloro-2-methyl-2-propanol), benzyl alcohol and benzalkonium chloride in the absence of a mineral suspension, said preparation in the form of a multi-dose formulation.

52. Preparation of claim 51, wherein the concentration of the preservatives in the solution is about 0.1 to about 2.0 w/v %.

53. Preparation of claim 51, wherein the concentration is about 0.01 to about 0.3 w/v %.

54. Preparation of claim 51 wherein one preservative is chlorobutanol (1,1,1-trichloro-2-methyl-2-propanol) which is present in the solution in a concentration of about 2-5 mg/ml.

55. Preparation of claim 51, wherein one preservative is benzyl alcohol which is present in the solution in a concentration of about 1-5 mg/ml.

56. Preparation of claim 51, wherein one preservative is benzalkonium chloride which is present in the solution in a concentration of about 0.01-0.05 mg/ml.

57. Preparation of claim 51, wherein the human protein is selected from the group consisting of EPO, G-CSF and proteins with plasminogen activator-like activity.

58. Preparation of claim 51, wherein the buffer capacity of the preparation is adjusted to a value of up to 10 mVa/l.

59. Preparation of claim 58, wherein the buffer capacity of the preparation is adjusted by the addition to the solution of a well tolerated buffer substance selected from the group consisting of glycol, sodium citrate, alkali phosphates, alkali carbonates, amino acid salts, malic acid salts, maleic acid, fumaric acid, tartaric acid, aspartic acid and mixtures thereof.

60. Preparation of claim 51, wherein the titration acidity of the preparation is adjusted to a value of up to 15 mVal/l before administration to a patient.

61. Preparation of claim 60, wherein the titration acidity of the preparation is adjusted by the addition to the solution of a well tolerated buffer substance selected from the group consisting of glycol, sodium citrate, alkali phosphates, alkali carbonates, amino acid salts, malic acid salts, maleic acid, fumaric acid, tartaric acid, aspartic acid and mixtures thereof.

62. Preparation of claim 51, wherein the preservatives are a mixture of benzyl alcohol and benzalkonium chloride present in concentrations of up to 10 mg/ml and up to 0.1 mg/ml, respectively.

63. Preparation of claim 51, wherein the preservative is a mixture of benzyl alcohol and chlorobutanol present in concentrations of up to 10 mg/ml each.

64. Preparation of claim 51, wherein the preservative is a mixture of chlorobutanol, benzyl alcohol and benzalkonium chloride present in concentrations of up to 10 mg/ml, up to 10 mg/ml and up to 0.1 mg/ml, respectively.

65. Preparation of claim 51, wherein the preservative is a mixture of benzyl alcohol present in a concentration of 3 to 6 mg/ml and benzalkonium chloride present in a concentration of 0.1 to 0.025 mg/ml.

66. A kit for the preparation of a human protein-containing pharmaceutical injection or infusion solution, comprising a packaged lyophilized human protein and a separately packaged aqueous reconstitution solvent containing a mixture of at least two preservatives selected from the group consisting of chlorobutanol, benzyl alcohol and benzalkonium chloride in an amount to provide a concentration of the preservatives in the injection or infusion solution of 0.001 to 2 w/v %, wherein the kit does not contain a mineral suspension.